Cytokeratin 5 (EP1601Y) + Cytokeratin 14 (LL002) Rabbit/Mouse Monoclonal Antibodies

Cytokeratin 5 (EP1601Y) + Cytokeratin 14 (LL002)
Tumor cells of lung squamous carcinoma are labeled by cytokeratin 5 + 14 antibody in a cytoplasmic pattern.

Cytokeratin 5 (EP1601Y) + Cytokeratin 14 (LL002) Rabbit/Mouse Monoclonal Antibodies

Updated: 2018-02-12 13:35:29

Cytokeratin 5 is an intermediate filament protein of 58 kD amongst the cytokeratin family. It is a type II (basic) cytokeratin. Antibodies to this protein identify basal cells of squamous and glandular epithelia, myoepithelia, and mesothelium.1 Cytokeratin 14 is a 50 kD polypeptide found in basal cells of squamous epithelia, some glandular epithelia, myoepithelium, and mesothelial cells.1 Anti-cytokeratin 5 has been useful in the differential diagnosis of metastatic carcinoma in the pleura versus epithelial mesothelioma.2 Anti-cytokeratin 14 has been demonstrated to be useful in differentiating squamous cell carcinomas from other epithelial tumors.3,4,6 Anti-Cytokeratin 5, along with anti-cytokeratin 14, has been found to have an application in identifying the basal-like phenotype of breast carcinoma.5,7-9

  1. Dabbs DJ. Diagnostic immunohistochemistry. 4th Edition. Philadelphia, PA: Elsevier Saunders, 2014. Print. P. 212.
  2. Comin CE, et al. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007; 31:1139-48.
  3. Reis-Filho JS, et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol. 2003; 11:1-8.
  4. Chu PG, et al. Cytokeratin 14 immunoreactivity distinguishes oncocytic tumour from its renal mimics: an immunohistochemical study of 63 cases. Histopathology. 2001; 39:455-62.
  5. Dabbs DJ, et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 2006; 19:1506-11.
  6. Chu PG, et al. Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours. Histopathology. 2001; 39:9-16.
  7. Livasy CA, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007; 38:197-204.
  8. Dabbs DJ. Diagnostic immunohistochemistry. 4th Edition. Philadelphia, PA: Elsevier Saunders, 2014. Print. P. 728-9.
  9. Gusterson BA, et al. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005; 7:143-8.

Specifications


  • Reactivity: paraffin
  • Visualization: cytoplasmic
  • Control: esophagus, squamous cell carcinoma
  • Dilution Range: N/A *

Package Inserts


IFU SDS

Ordering Information

For in vitro diagnostic (IVD) use in USA

1 mL predilute905H-07
7 mL predilute905H-08

For in vitro diagnostic (IVD) use in Canada

1 mL predilute905H-07
7 mL predilute905H-08

For in vitro diagnostic (IVD) use in Europe

1 mL predilute905H-07
7 mL predilute905H-08

For research use only (RUO) in Japan

1 mL predilute905H-07-RUO
7 mL predilute905H-08-RUO

 

To request information on this product in additional countries, please click the button below.

Request More Information